Addressing Treatment Gaps in Gout
Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering...
Radio and PodcastLive Radio & PodcastsBusiness
The Bio Report
The Bio Report podcast, hosted by veteran journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
The Bio Report Podcast Guide
Listen to The Bio Report, a Business podcast by Levine Media Group. Stream 614 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Business podcasts.
Episodes
20 episodes are loaded now from a catalog of 614. More episodes can be opened from this page.
Discover More
Explore Business podcasts, United States podcasts and English podcasts.
Episodes
20 of 614 episodesAn Off-the-Shelf Cell Therapy to Calm Cytokine Storms
Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast ha...
Slowing Disability in MS
Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop t...
Tuning, Rather than Blocking, Immunity in IBD
The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection r...
Intercepting Cancer When DNA Surveillance Fails
Many people with the genetic condition Lynch syndrome live with the near‑certainty that they will one day develop cancer and have few option...
Targeting Psychosis in Alzheimer’s Disease
Alzheimer’s disease drug development has long focused on slowing memory loss, but for many families, the tipping point that makes home care...
A Class Action Suits Moves RICO from Mobsters to Medicine
RICO, the Racketeer Influenced and Corrupt Organizations Act, was originally designed to prosecute organized crime. Today, it sits at the ce...
Outsmarting Resistance with Rhythm
Pancreatic cancer remains one of oncology’s deadliest diagnoses, with standard treatments often offering only transient tumor shrinkage at t...
Editing Away Autoimmunity at the HLA Source
Human leukocyte antigen, or HLA, genes, help the immune system tell the difference between the body’s own tissues and outside threats. In so...
Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress
Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost-efficient dru...
Reprogramming Cancer from Within
Leukemia once threatened Aaron Viny’s life, but now it defines his mission. Diagnosed with acute lymphoblastic leukemia as a college student...
A Strategic Turn from Obesity to Cancer
When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but...
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
A One‑Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer Non–muscle invasive bladder cancer is a common, slow-progressing form of...
Reprogramming T Cells to Cross the Brain’s Border
One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has devel...
A Billion-Dollar Bet on AI-First Drug Development
Despite the emergence of new modalities and drug development technologies, the cost and time to produce new therapies has changed little, an...
Finding New Targets on the Surface of Misfolded Proteins
Finding New Targets on the Surface of Misfolded One of the biggest hurdles in drug development is targeting proteins found in both healthy a...
Targeting Tumors from the Inside Out
Systemic chemotherapy remains the foundation of cancer treatment, but its widespread toxicity too often cuts short potential therapeutic ben...
An Effort to Detect and Treat Alzheimer’s at Its Earliest Stages
One of the challenges in treating the neurodegenerative condition Alzheimer’s disease is intervening early enough in the course of illness t...
The Year in Biotech and What’s Ahead for 2026
Biotech stocks staged a dramatic turnaround in 2025, with the XBI well outpacing the S&P 500 despite concerns over leadership changes at the...
Developing an Alternative to Opioids for Post-Surgical Pain
The approach to post-surgical pain relief has relied on short-duration treatments and notably opioids. That’s led to the associated risks of...